ArticleOncogene2015
Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer.
Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Impact of NDUFAF6 on breast cancer prognosis: linking mitochondrial regulation to immune response and PD-L1 expression.Cancer cell international · 2024Article
- Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer.Cancer cell international · 2023Review
- Tumor-derived OBP2A promotes prostate cancer castration resistance.The Journal of experimental medicine · 2023Article
- A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis.Frontiers in oncology · 2022Article
- A prognostic nomogram based on competing endogenous RNA network for clear-cell renal cell carcinoma.Cancer medicine · 2021Article
- Overview of research on fusion genes in prostate cancer.Translational cancer research · 2020Review
- Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression.Oncogene · 2019Article
- Protein interaction disruption in cancer.BMC cancer · 2019Article
- Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.International journal of cancer · 2018Article
- The future of prostate cancer research: bringing data together, looking back and forward.Translational andrology and urology · 2018Review
- Novel transcription-induced fusion RNAs in prostate cancer.Oncotarget · 2017Article
- A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in cancer.Oncotarget · 2017Article
- Discovering and understanding oncogenic gene fusions through data intensive computational approaches.Nucleic acids research · 2016Review
- Fusion transcript loci share many genomic features with non-fusion loci.BMC genomics · 2015Article
- Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads.Nature biotechnology · 2014Article
- DLG5 in cell polarity maintenance and cancer development.International journal of biological sciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene fusions, mainly between TMPRSS2 and ERG, are frequent early genomic rearrangements in prostate cancer (PCa). In order to discover novel genomic fusion events, we applied whole-genome paired-end sequencing to identify structural alterations present in a primary PCa patient (G089) and in a PCa cell line (PC346C). Overall, we identified over 3800 genomic rearrangements in each of the two samples as compared with the reference genome. Correcting these structural variations for polymorphisms using whole-genome sequences of 46 normal samples, the numbers of cancer-related rearrangements were 674 and 387 for G089 and PC346C, respectively. From these, 192 in G089 and 106 in PC346C affected gene structures. Exclusion of small intronic deletions left 33 intergenic breaks in G089 and 14 in PC346C. Out of these, 12 and 9 reassembled genes with the same orientation, capable of generating a feasible fusion transcript. Using PCR we validated all the reliable predicted gene fusions. Two gene fusions were in-frame: MPP5-FAM71D in PC346C and ARHGEF3-C8ORF38 in G089. Downregulation of FAM71D and MPP5-FAM71D transcripts in PC346C cells decreased proliferation; however, no effect was observed in the RWPE-1-immortalized normal prostate epithelial cells. Together, our data showed that gene rearrangements frequently occur in PCa genomes but result in a limited number of fusion transcripts. Most of these fusion transcripts do not encode in-frame fusion proteins. The unique in-frame MPP5-FAM71D fusion product is important for proliferation of PC346C cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.